viewQ BioMed Inc.

Q BioMed to apply for Orphan Drug status with FDA, European regulators for its pediatric autism drug

QBM-001 aims to treat toddlers with pediatric nonverbal autism

New York company may launch clinical trials of QBM-001 in the first quarter of 2020

Q BioMed Inc (OTCMKTS:QBIO) announced Tuesday it plans to apply for Orphan Drug status with US and European regulators for its pediatric autism drug candidate QBM-001.

QBM-001 aims to treat toddlers with pediatric nonverbal autism who suffer from nonverbal or minimally verbal capabilities (PMVA). The company says there is no effective treatment available to treat an estimated 250,000 children born each year worldwide (20,000 in the US) with the affliction.

Q BioMed said that this month it will ask the US Food and Drug Administration and the European Medicines Agency for Orphan designation, which is given to drugs that treat less than 200,000 patients per year in the US. QBM-001 should be able to treat 15,000 US children, the company said.

READ: Q BioMed uncovers first biomarkers for pediatric nonverbal autism

Orphan Drug designation offers clinical development benefits including tax credits and eligibility for seven years of market exclusivity in the US and 10 years in Europe.

The company said its application to the FDA and EMA will be based on its recent breakthrough discovery of two biomarkers that identifies PMVA. The company's study examined 1,953 autistic biomarkers.

"Q BioMed is committed to delivering relief to the children and families that are impacted by this condition,” said CEO Denis Corin. “The emotional strain of never talking with one's child can be severe, and the direct financial costs over a lifetime are estimated to be $4.5 million per family."

In the meantime, the New York-based company’s second phase of QBM-001’s formulation is expected to be finalized in August 2019.

At that time, Q BioMed said it will request a pre-investigational new drug meeting with the FDA and similar discussions with Europe's EMA. Based on regulatory guidance, Q BioMed anticipates filing its new drug meeting submissions, including its current clinical trial design, in December.

And clinical trials may commence as early as the first quarter of 2020, the company said. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Q BioMed Inc.

Price: 1.6 USD

Market: OTCQB
Market Cap: $36.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...



Q BioMed to bring metastatic bone pain drug to patients around the world...

Q BioMed Inc's (OTCQB:QBIO) Kristin Keller tells Proactive the New York-based biotech has launched a Named Patient Program (NPP) to bring its non-opioid bone metastasis pain drug Strontium89 to patients around the world starting in September. Keller says the NPP allows Strontium89 to be provided...

1 day, 4 hours ago

2 min read